Skip to main content
Erschienen in: Pediatric Radiology 4/2011

01.04.2011 | Original Article

Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis

verfasst von: Jyoti Bajpai, Shivanand Gamnagatti, Rakesh Kumar, Vishnubhatla Sreenivas, Mehar Chand Sharma, Shah Alam Khan, Shishir Rastogi, Arun Malhotra, Rajni Safaya, Sameer Bakhshi

Erschienen in: Pediatric Radiology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Histological necrosis, the current standard for response evaluation in osteosarcoma, is attainable after neoadjuvant chemotherapy.

Objective

To establish the role of surrogate markers of response prediction and evaluation using MRI in the early phases of the disease.

Materials and methods

Thirty-one treatment-naïve osteosarcoma patients received three cycles of neoadjuvant chemotherapy followed by surgery during 2006–2008. All patients underwent baseline and post-chemotherapy conventional, diffusion-weighted and dynamic contrast-enhanced MRI. Taking histological response (good response ≥90% necrosis) as the reference standard, various parameters of MRI were compared to it. A tumor was considered ellipsoidal; volume, average tumor plane and its relative value (average tumor plane relative/body surface area) was calculated using the standard formula for ellipse. Receiver operating characteristic curves were generated to assess best threshold and predictability. After deriving thresholds for each parameter in univariable analysis, multivariable analysis was carried out.

Results

Both pre-and post-chemotherapy absolute and relative-size parameters correlated well with necrosis. Apparent diffusion coefficient did not correlate with necrosis; however, on adjusting for volume, significant correlation was found. Thus, we could derive a new parameter: diffusion per unit volume.

Conclusion

In osteosarcoma, chemotherapy response can be predicted and evaluated by conventional and diffusion-weighted MRI early in the disease course and it correlates well with necrosis. Further, newly derived parameter diffusion per unit volume appears to be a sensitive substitute for response evaluation in osteosarcoma.
Literatur
1.
Zurück zum Zitat Saeter G, Hoie J, Stenwig AE et al (1995) Systemic relapse of patients with osteogenic sarcoma: prognostic factors for long term survival. Cancer 75:1084–1093PubMedCrossRef Saeter G, Hoie J, Stenwig AE et al (1995) Systemic relapse of patients with osteogenic sarcoma: prognostic factors for long term survival. Cancer 75:1084–1093PubMedCrossRef
2.
Zurück zum Zitat Enneking WF, Spanier SS, Goodman MA (1980) A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 153:106–120PubMed Enneking WF, Spanier SS, Goodman MA (1980) A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 153:106–120PubMed
3.
Zurück zum Zitat Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedCrossRef Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedCrossRef
4.
Zurück zum Zitat Uhl M, Saueressig U, Koehler G et al (2006) Evaluation of tumor necrosis during chemotherapy with diffusion-weighted MR imaging: preliminary results in osteosarcomas. Pediatr Radiol 36:1306–1311PubMedCrossRef Uhl M, Saueressig U, Koehler G et al (2006) Evaluation of tumor necrosis during chemotherapy with diffusion-weighted MR imaging: preliminary results in osteosarcomas. Pediatr Radiol 36:1306–1311PubMedCrossRef
5.
Zurück zum Zitat Dudeck O, Zeile M, Pink D et al (2003) Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging 27:1109–1113CrossRef Dudeck O, Zeile M, Pink D et al (2003) Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging 27:1109–1113CrossRef
6.
Zurück zum Zitat Moffat BA, Chenevert TL, Meyer CR et al (2006) The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8:259–267PubMedCrossRef Moffat BA, Chenevert TL, Meyer CR et al (2006) The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8:259–267PubMedCrossRef
7.
Zurück zum Zitat Koh DM, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR 188:1622–1635PubMedCrossRef Koh DM, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR 188:1622–1635PubMedCrossRef
8.
Zurück zum Zitat Schnall MD, Blume J, Bluemke DA et al (2006) Diagnostic architectural and dynamic features at breast MR imaging: multicenter study 1. Radiology 238:42–53PubMedCrossRef Schnall MD, Blume J, Bluemke DA et al (2006) Diagnostic architectural and dynamic features at breast MR imaging: multicenter study 1. Radiology 238:42–53PubMedCrossRef
9.
Zurück zum Zitat Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer, New YorkCrossRef Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer, New YorkCrossRef
10.
Zurück zum Zitat Picci P, Bacci G, Campanacci M et al (1985) Histological evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 56:1515PubMedCrossRef Picci P, Bacci G, Campanacci M et al (1985) Histological evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 56:1515PubMedCrossRef
11.
Zurück zum Zitat Bacci G, Picci P, Ruggieri P et al (1990) Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Instituto Rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 65:2539–2553PubMedCrossRef Bacci G, Picci P, Ruggieri P et al (1990) Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Instituto Rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 65:2539–2553PubMedCrossRef
12.
Zurück zum Zitat Winkler K, Beron G, Delling G et al (1988) Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6:329–337PubMed Winkler K, Beron G, Delling G et al (1988) Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6:329–337PubMed
13.
Zurück zum Zitat Withers HR, Lee SP (2006) Modeling growth kinetics and statistical distribution of oligometastases. Semin Radiat Oncol 16:111–119PubMedCrossRef Withers HR, Lee SP (2006) Modeling growth kinetics and statistical distribution of oligometastases. Semin Radiat Oncol 16:111–119PubMedCrossRef
14.
Zurück zum Zitat Pervaiz S (2002) Anti-cancer drugs of today and tomorrow: are we close to making the turn from treating to curing cancer? Curr Pharm Des 8:1723–1734PubMedCrossRef Pervaiz S (2002) Anti-cancer drugs of today and tomorrow: are we close to making the turn from treating to curing cancer? Curr Pharm Des 8:1723–1734PubMedCrossRef
15.
Zurück zum Zitat Nathan SS, DiResta GR, Casas-Ganem JE et al (2005) Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 11:2389–2397PubMedCrossRef Nathan SS, DiResta GR, Casas-Ganem JE et al (2005) Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 11:2389–2397PubMedCrossRef
16.
Zurück zum Zitat Brisse H, Ollivier L, Edeline V et al (2004) Imaging of malignant tumors of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol 34:595–605PubMedCrossRef Brisse H, Ollivier L, Edeline V et al (2004) Imaging of malignant tumors of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol 34:595–605PubMedCrossRef
17.
Zurück zum Zitat Jones DN, McCowage GB, Sostman HD et al (1996) Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 37:1438–1444PubMed Jones DN, McCowage GB, Sostman HD et al (1996) Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 37:1438–1444PubMed
18.
Zurück zum Zitat Kim MS, Lee SY, Cho WH et al (2008) Initial tumor size predicts histologic response and survival in localized osteosarcoma patients. J Surg Oncol 97:456–461PubMedCrossRef Kim MS, Lee SY, Cho WH et al (2008) Initial tumor size predicts histologic response and survival in localized osteosarcoma patients. J Surg Oncol 97:456–461PubMedCrossRef
19.
Zurück zum Zitat Vander Woude HJ, Bloem JL, Hogendoorn PC (1998) Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing’s sarcoma: review of current imaging modalities. Skeletal Radiol 27:57–71CrossRef Vander Woude HJ, Bloem JL, Hogendoorn PC (1998) Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing’s sarcoma: review of current imaging modalities. Skeletal Radiol 27:57–71CrossRef
20.
Zurück zum Zitat Kim MS, Lee SY, Cho WH et al (2008) Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Ann Surg Oncol 15:906–914PubMedCrossRef Kim MS, Lee SY, Cho WH et al (2008) Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Ann Surg Oncol 15:906–914PubMedCrossRef
21.
Zurück zum Zitat Lee JA, Kim MS, Kim DH et al (2008) Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma. Pediatr Blood Cancer 50:195–200PubMedCrossRef Lee JA, Kim MS, Kim DH et al (2008) Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma. Pediatr Blood Cancer 50:195–200PubMedCrossRef
22.
Zurück zum Zitat Groninger E, Proost JH, de Graaf SS (2004) Pharmacokinetic studies in children with cancer. Crit Rev Oncol Hematol 52:173–197PubMedCrossRef Groninger E, Proost JH, de Graaf SS (2004) Pharmacokinetic studies in children with cancer. Crit Rev Oncol Hematol 52:173–197PubMedCrossRef
23.
Zurück zum Zitat Kaste SC, Liu T, Billups CA et al (2004) Tumor size as a predictor of outcome in pediatric non-metastatic osteosarcoma of the extremity. Pediatr Blood Cancer 43:723–728PubMedCrossRef Kaste SC, Liu T, Billups CA et al (2004) Tumor size as a predictor of outcome in pediatric non-metastatic osteosarcoma of the extremity. Pediatr Blood Cancer 43:723–728PubMedCrossRef
24.
Zurück zum Zitat Uhl M, Saueressig U, van Buiren M et al (2006) Preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol 41:618–623PubMedCrossRef Uhl M, Saueressig U, van Buiren M et al (2006) Preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol 41:618–623PubMedCrossRef
25.
Zurück zum Zitat Hayashida Y, Yakushiji T, Awai K et al (2006) Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur Radiol 16:2637–2643PubMedCrossRef Hayashida Y, Yakushiji T, Awai K et al (2006) Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur Radiol 16:2637–2643PubMedCrossRef
26.
Zurück zum Zitat Theilmann RJ, Borders R, Trouard TP et al (2004) Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6:831–837PubMedCrossRef Theilmann RJ, Borders R, Trouard TP et al (2004) Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6:831–837PubMedCrossRef
27.
Zurück zum Zitat Chenevert TL, Stegman LD, Taylor JM et al (2000) Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92:2029–2036PubMedCrossRef Chenevert TL, Stegman LD, Taylor JM et al (2000) Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92:2029–2036PubMedCrossRef
28.
Zurück zum Zitat Mardor Y, Pfeffer R, Spiegelmann R et al (2003) Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 21:1094–1100PubMedCrossRef Mardor Y, Pfeffer R, Spiegelmann R et al (2003) Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 21:1094–1100PubMedCrossRef
29.
Zurück zum Zitat Deng J, Miller FH, Rhee TK et al (2006) Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 17:1195–1200PubMedCrossRef Deng J, Miller FH, Rhee TK et al (2006) Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 17:1195–1200PubMedCrossRef
30.
Zurück zum Zitat Dyke JP, Panicek DM, Healey JH et al (2003) Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast enhanced MR imaging. Radiology 228:271–278PubMedCrossRef Dyke JP, Panicek DM, Healey JH et al (2003) Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast enhanced MR imaging. Radiology 228:271–278PubMedCrossRef
31.
Zurück zum Zitat Guo JY, Reddick WE (2009) DCE-MRI pixel-by-pixel quantitative curve pattern analysis and its application to osteosarcoma. J Magn Reson Imag 30:177–184CrossRef Guo JY, Reddick WE (2009) DCE-MRI pixel-by-pixel quantitative curve pattern analysis and its application to osteosarcoma. J Magn Reson Imag 30:177–184CrossRef
32.
Zurück zum Zitat Shin KH, Moon SH, Suh JS et al (2000) Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop Relat Res 376:200–208PubMedCrossRef Shin KH, Moon SH, Suh JS et al (2000) Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop Relat Res 376:200–208PubMedCrossRef
Metadaten
Titel
Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis
verfasst von
Jyoti Bajpai
Shivanand Gamnagatti
Rakesh Kumar
Vishnubhatla Sreenivas
Mehar Chand Sharma
Shah Alam Khan
Shishir Rastogi
Arun Malhotra
Rajni Safaya
Sameer Bakhshi
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
Pediatric Radiology / Ausgabe 4/2011
Print ISSN: 0301-0449
Elektronische ISSN: 1432-1998
DOI
https://doi.org/10.1007/s00247-010-1876-3

Weitere Artikel der Ausgabe 4/2011

Pediatric Radiology 4/2011 Zur Ausgabe

PET kann infarktgefährdete Koronararterien entdecken

04.06.2024 Koronare Herzerkrankung Nachrichten

Der Nachweis aktiver Plaques mittels 18F-Natriumfluorid-PET hilft nicht nur, infarktgefährdete Patienten, sondern auch infarktgefährdete Koronararterien zu erkennen. Von einer gezielten Behandlung vulnerabler Plaques ist man trotzdem weit entfernt.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.